Poyurovsky M, Braverman L, Weizman A., et al. - In patients with bipolar disorder, obsessive-compulsive disorder (OCD) is a prevalent and clinically significant comorbid condition, so researchers analyzed the impact of quetiapine monotherapy in patients with bipolar depression and comorbid obsessive-compulsive disorder. For this open-label, short-term, prospective investigation, participants were 16 patients (three men and 13 women, aged 18-56 years) hospitalized for acute bipolar depression, who also met the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria for OCD. Candidates were treated with quetiapine in a dose range of 150–600 mg (mean 347 mg) for a mean duration of 4.3 ± 1.4 weeks (range 3–7 weeks). A statistically significant reduction from baseline in the relevant rating scales for measuring depressive, manic, and OCD symptoms was linked with quetiapine therapy; quetiapine was also well tolerated. Sedation, orthostatic hypotension and constipation were the most frequently seen side effects. In future controlled trials, it is important to discuss the durability of the positive therapeutic impact of quetiapine monotherapy in patients with bipolar disorder/OCD comorbidity and the need for subsequent augmentation with anti-OCD agents.